122 related articles for article (PubMed ID: 17584031)
1. Microarray-based identification of new targets for specific therapies in pediatric leukemia.
den Boer ML; Pieters R
Curr Drug Targets; 2007 Jun; 8(6):761-4. PubMed ID: 17584031
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of acute leukemia.
Cheok MH; Lugthart S; Evans WE
Annu Rev Pharmacol Toxicol; 2006; 46():317-53. PubMed ID: 16402908
[TBL] [Abstract][Full Text] [Related]
3. Relapse of acute lymphoblastic leukemia in children in the context of microarray analyses.
Szczepanek J; Styczyński J; Haus O; Tretyn A; Wysocki M
Arch Immunol Ther Exp (Warsz); 2011 Feb; 59(1):61-8. PubMed ID: 21246408
[TBL] [Abstract][Full Text] [Related]
4. Genomic and transcriptomic profiles and in vitro resistance to mitoxantrone and idarubicin in pediatric acute leukemias.
Laskowska J; Lewandowska-Bieniek J; Szczepanek J; Styczyński J; Tretyn A
J Gene Med; 2016 Aug; 18(8):165-79. PubMed ID: 27280600
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
[TBL] [Abstract][Full Text] [Related]
6. Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia.
Bhojwani D; Moskowitz N; Raetz EA; Carroll WL
Paediatr Drugs; 2007; 9(3):149-56. PubMed ID: 17523695
[TBL] [Abstract][Full Text] [Related]
7. Integrative computational in-depth analysis of dysregulated miRNA-mRNA interactions in drug-resistant pediatric acute lymphoblastic leukemia cells: an attempt to obtain new potential gene-miRNA pathways involved in response to treatment.
Mesrian Tanha H; Mojtabavi Naeini M; Rahgozar S; Moafi A; Honardoost MA
Tumour Biol; 2016 Jun; 37(6):7861-72. PubMed ID: 26700663
[TBL] [Abstract][Full Text] [Related]
8. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia.
Steinbach D; Schramm A; Eggert A; Onda M; Dawczynski K; Rump A; Pastan I; Wittig S; Pfaffendorf N; Voigt A; Zintl F; Gruhn B
Clin Cancer Res; 2006 Apr; 12(8):2434-41. PubMed ID: 16638849
[TBL] [Abstract][Full Text] [Related]
9. Childhood and adolescent lymphoid and myeloid leukemia.
Pui CH; Schrappe M; Ribeiro RC; Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2004; ():118-45. PubMed ID: 15561680
[TBL] [Abstract][Full Text] [Related]
10. Building better therapy for children with acute lymphoblastic leukemia.
Carroll WL; Raetz EA
Cancer Cell; 2005 Apr; 7(4):289-91. PubMed ID: 15837616
[TBL] [Abstract][Full Text] [Related]
11. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status.
Andersson A; Ritz C; Lindgren D; Edén P; Lassen C; Heldrup J; Olofsson T; Råde J; Fontes M; Porwit-Macdonald A; Behrendtz M; Höglund M; Johansson B; Fioretos T
Leukemia; 2007 Jun; 21(6):1198-203. PubMed ID: 17410184
[TBL] [Abstract][Full Text] [Related]
12. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
[TBL] [Abstract][Full Text] [Related]
13. New Candidate Genes for Lack of Sensitivity to Therapy in Pediatric Leukemias.
Bereza W; Szczepanek J; Laskowska J; Tretyn A
Curr Cancer Drug Targets; 2017; 17(4):333-343. PubMed ID: 27928969
[TBL] [Abstract][Full Text] [Related]
14. The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities.
Liaw TY; Chang MH; Kavallaris M
Curr Drug Targets; 2007 Jun; 8(6):739-49. PubMed ID: 17584029
[TBL] [Abstract][Full Text] [Related]
15. Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy.
Krishnan V; Rajasekaran AK
Clin Pharmacol Ther; 2014 Feb; 95(2):168-78. PubMed ID: 24013811
[TBL] [Abstract][Full Text] [Related]
16. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
Svirnovski AI; Shman TV; Serhiyenka TF; Savitski VP; Smolnikova VV; Fedasenka UU
Hematology; 2009 Aug; 14(4):204-12. PubMed ID: 19635183
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of gene expression in relapsed childhood B-acute lymphoblastic leukemia.
Chow YP; Alias H; Jamal R
BMC Cancer; 2017 Feb; 17(1):120. PubMed ID: 28183295
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of rs62527607 [GT] single nucleotide polymorphism located in BAALC gene in children with acute leukemia using mismatch PCR-RFLP.
Nadimi M; Rahgozar S; Moafi A; Tavassoli M; Mesrian Tanha H
Cancer Genet; 2016; 209(7-8):348-53. PubMed ID: 27372260
[TBL] [Abstract][Full Text] [Related]
19. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
Pierro J; Hogan LE; Bhatla T; Carroll WL
Expert Rev Anticancer Ther; 2017 Aug; 17(8):725-736. PubMed ID: 28649891
[TBL] [Abstract][Full Text] [Related]
20. FLT3 as a therapeutic target in childhood acute leukemia.
Stubbs MC; Armstrong SA
Curr Drug Targets; 2007 Jun; 8(6):703-14. PubMed ID: 17584026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
